Vonoprazan‐containing Helicobacter pylori triple therapies contribution to global antimicrobial resistance

Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan

(2020) Sho Suzuki et al.   GUT

PPI‐amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta‐analysis

(2020) Cai‐Ping Gao et al.   HELICOBACTER

High-dose dual therapy is effective as first-line treatment for Helicobacter pylori infection

(2020) Kadir Ozturk et al.   Turkish Journal of Gastroenterology

A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial

(2019) Wei-Chen Tai et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

High‐dose PPI‐amoxicillin dual therapy with or without bismuth for first‐line Helicobacter pylori therapy: A randomized trial

(2019) Lou Yu et al.   HELICOBACTER

Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori

(2019) Takahisa Furuta et al.   DIGESTION

Vonoprazan-Based Triple-Therapy Could Improve Efficacy of the Tailored Therapy of Helicobacter pylori Infection

(2019) Tetsuya Shinmura et al.   Journal of Gastrointestinal and Liver Diseases

Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency

(2018) David Y. Graham et al.   Clinical Gastroenterology and Hepatology

Update on the Use of Vonoprazan: A Competitive Acid Blocker

(2018) David Y. Graham et al.   GASTROENTEROLOGY

Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori

(2018) Min Li et al.   HELICOBACTER

Comment #2 on “First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin”

(2018) Davide Giuseppe Ribaldone et al.   Gastroenterology Research and Practice

Illusions regardingHelicobacter pyloriclinical trials and treatment guidelines

(2017) David Y Graham   GUT

Effect on Helicobacter pylori eradication therapy against gastric cancer in Japan

(2017) Momoko Tsuda et al.   HELICOBACTER

Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori : A multicenter, prospective, randomized trial

(2017) Soichiro Sue et al.   HELICOBACTER

Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?

(2017) Shou Quan Dong et al.   HELICOBACTER

Failure of optimized dual proton pump inhibitor amoxicillin therapy: What now?

(2017) DavidY Graham et al.   Saudi Journal of Gastroenterology

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy forHelicobacter pylorieradication: a phase III, randomised, double-blind study

(2016) Kazunari Murakami et al.   GUT

Vonoprazan Helicobacter pylori eradication therapy: ethical and interpretation issues

(2016) David Y Graham   GUT

Role of bismuth in improvingHelicobacter pylorieradication with triple therapy

(2016) Maria Pina Dore et al.   GUT

Understanding antimicrobial stewardship: Disease severity treatment thresholds and antimicrobial alternatives among organic and conventional calf producers

(2016) Greg Habing et al.   PREVENTIVE VETERINARY MEDICINE

High-dose Dual Therapy Is Superior to Standard First-line or Rescue Therapy for Helicobacter pylori Infection

(2015) Jyh-Chin Yang et al.   Clinical Gastroenterology and Hepatology

Kyoto global consensus report onHelicobacter pylorigastritis

(2015) Kentaro Sugano et al.   GUT

A new approach for elimination of gastric cancer deaths in Japan

(2012) Masahiro Asaka   INTERNATIONAL JOURNAL OF CANCER

New concepts of resistance in the treatment of Helicobacter pylori infections

(2008) David Y Graham et al.   Nature clinical practice. Gastroenterology & hepatology